Similarly, a higher TNFRSF9 CD8+ T cells infiltration was addressed to be associated with greater reduction of tumor size (p = 0.003) and better PFS (p = 0.012) in ccRCC patients receiving nivolumab (70). The gene discussed is CD8A; the disease is neoplasm.